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The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) has several adaptations that
allow the virus to evade antibody neutralization. Nevertheless, a few broadly cross-reactive neutralizing
antibodies as well as reagents containing portions of CD4, the HIV receptor, have demonstrated partial efficacy
in suppressing viral replication. One type of reagent designed for improved HIV neutralization fuses the CD4
D1-D2 domains to the variable regions of an antibody recognizing the CD4-induced (CD4i) coreceptor binding
site on the gp120 portion of the HIV envelope spike. We designed, expressed, purified, and tested the
neutralization potencies of CD4-CD4i antibody reagents with different architectures, antibody combining sites,
and linkers. We found that fusing CD4 to the heavy chain of the CD4i antibody E51 yields a bivalent reagent
including an antibody Fc region that expresses well, is expected to have a long serum half-life, and has
comparable or greater neutralization activity than well-known broadly neutralizing anti-HIV antibodies. A
CD4 fusion with the anti-HIV carbohydrate antibody 2G12 also results in a potent neutralizing reagent with
more broadly neutralizing activity than 2G12 alone.
The envelope spike of human immunodeficiency virus type 1
(HIV-1), a trimer of gp120/gp41 heterodimers, utilizes a num-
ber of strategies to avoid antibodies (Abs) elicited by the hu-
moral immune response. These include variable loops, heavy
glycosylation (36), conformational masking of key functional
sites (19), and an architecture and surface density that reduce
bivalent Ab engagement (18). Nevertheless, a small number of
broadly cross-reactive neutralizing Abs have been found and
extensively characterized (5, 32, 41). The targets of these Abs
include the membrane proximal region of gp41 (24, 42), a
cluster of high-mannose carbohydrates on gp120 (29), and the
HIV receptor (CD4)-binding site (3, 28). A combination of
several of these Abs has been evaluated in clinical trials as a
passive immunotherapy to reduce viral rebound during an in-
terruption of antiretroviral therapy (34).
Several CD4-containing proteins have also been explored
clinically as possible therapeutics for treating HIV-1: soluble
CD4 (13, 16), a CD4-Fc fusion protein (7), and the tetravalent
CD4-immunoglobulin G2 (CD4-IgG2; PRO 542) reagent (1,
17). In patients with advanced disease, CD4-IgG2 treatment
led to a 0.5 log10 mean reduction in viral load (17). In addi-
tion, D1D2-Igtp, an approximately dodecameric CD4 reagent
created as a chimeric IgG1/IgA fusion protein (2), exhibited
very potent HIV neutralization activity and targeted HIV-
infected cells for lysis by natural killer cells (14).
Another approach to targeting gp120 is a fusion protein
composed of CD4 linked to the variable regions of a CD4-
induced (CD4i) Ab (11). CD4i Abs represent a potentially
promising class of Abs because they bind to the conserved
HIV-1 coreceptor binding site on gp120, which is exposed after
a conformational change resulting from binding to CD4 (25,
27, 38). Examples of CD4i Abs include 17b (33), E51 (39), m9
(40), 412d (8), and 21c (38). These Abs are often broadly
cross-reactive but generally show little neutralization potency
in vivo due to limited steric accessibility when gp120 on the
viral membrane is bound to CD4 on the surface of the target
cell (20). Fusing CD4 to the combining site of a CD4i Ab solves
the accessibility problem since the Ab epitope would be ex-
posed by CD4 binding when the virion is not bound to the
target cell. This class of reagent has two other favorable fea-
tures: bivalent binding and targeting of functionally critical
epitopes on gp120, the CD4 and coreceptor binding sites. One
such reagent, sCD4-17b (referred to here as CD4-scFv17b),
contains the first two domains of CD4 linked to the single-
chain fragment variable (scFv) form of the CD4i Ab 17b (Fig.
1) (11). This reagent was shown to potently neutralize multiple
primary strains of HIV-1 (11), suggesting that CD4-CD4i Ab
fusion proteins are promising candidates for passive immuni-
zation or gene therapy trials.
Critical properties for CD4-containing reagents include
their breadth of neutralization activity, half-life, and, for re-
agents used in a gene therapy context, their expression level.
We have undertaken a systematic effort to develop the optimal
architecture for a CD4-CD4i Ab reagent by designing, con-
structing, and testing reagents with different CD4i Ab combin-
ing sites and including an Ab Fc region to increase valency and
serum half-life (7). We varied the arrangements of the Ab
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combining sites; the lengths, attachments, and forms of the
linking regions; and the ways in which CD4 was fused to the
CD4i Ab (Fig. 1). CD4-CD4i Ab reagents were evaluated using
in vitro neutralization assays across a broad range of clade A,
B, and C HIV-1 strains. One promising reagent, a fusion of
CD4 domains 1 and 2 (D1-D2) to the heavy chain of the E51
CD4i Ab, was expressed at high levels in mammalian cells and
exhibited neutralization potencies that compared favorably
with or exceeded those of known broadly neutralizing Abs such
as 4E10, b12, 2G12, and 2F5.
Since much of the activity of our CD4-CD4i reagents re-
sulted from the CD4 component, we also explored the effects
of attaching CD4 to an Ab with a different quaternary struc-
ture. The anticarbohydrate Ab 2G12 is unusual in that its
heavy chains are involved in a domain swap creating a rigid
(Fab)2 unit in which the combining sites are separated by
35Å (6). This domain swapping tendency also leads to the
formation of 2G12 dimers containing two (Fab)2 units and two
Fc regions, which form when the domain swapping occurs
intermolecularly between two IgGs rather than intramolecu-
larly between the two Fab arms of a single IgG (37). The 2G12
dimer is 50- to 80-fold more potent than monomeric 2G12 in
neutralizing clade B 2G12-sensitive strains; however, neither
form of 2G12 neutralizes clade C strains of HIV-1 (37). In
order to assess the effects of adding CD4 to the 2G12 mono-
mer and dimer architectures and to explore whether addition
of CD4 would broaden the range of HIV-1 strains that are
sensitive to 2G12, we constructed CD4-2G12 fusion proteins
and tested their neutralization potencies (Fig. 1). We found
that these hybrid reagents had potent neutralizing activities
with both the CD4 and Ab combining site components appar-
ently contributing to this behavior.
MATERIALS AND METHODS
Isolation of genes encoding the 21c Ab. 21c IgG was purified from an Epstein-
Barr virus-transformed human B-cell line obtained from James Robinson (Tu-
lane University). N-terminal amino acid sequencing was performed after treat-
ment with Pfu pyroglutamate aminopeptidase to remove blocking pyroglutamate,
FIG. 1. Schematic depiction of CD4-CD4i reagents and related molecules. VH, variable domain of the IgG heavy chain (HC); VL, variable
domain of the IgG light chain (LC), CH1, constant region 1 of the HC; CL, constant region of the LC; Fc, CH2 and CH3 domains of dimerized HCs;
CD4 D1-D2, N-terminal two domains of CD4; scFv, single-chain fragment variable (VH and VL domains of an IgG); CD4HC, CD4 linked to the
VH domain of an IgG; CD4LC, CD4 linked to the VL domain of an IgG; CD4HC,LC, CD4 linked to the VH and VL domains of an IgG.
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and 5 primers were designed based on these sequences. Heavy and light chain
genes were obtained by cDNA amplification using a SMART RACE kit (Clon-
tech). The 3 primers were the human CH1 (constant region 1 of the heavy chain)
domain primer CAGCTCCACCCTCTTGTCCACCTTGGTGTTGCTGGG
and the human  constant domain primer CTAAGAACATTCTGCATGGGC
CATTGTCTTCTCC. Bridge PCR was used to generate the full-length heavy
chain.
Materials. Genes encoding the variable regions (variable heavy and variable
light, VH and VL, or the intact light chain VL-CL, where CL refers to the constant
light domain) of the E51, m9, and 412d Abs were synthesized (BlueHeron
Biotechnologies or Integrated DNA Technologies). Intact IgG genes were con-
structed by subcloning the relevant variable sequences onto a human IgG1
sequence. The 2G12 and anti-glycoprotein D (gD) IgG genes were obtained
from Dennis Burton (The Scripps Research Institute). The CD4-scFv17b gene
(11) was obtained from Ed Berger (Laboratory of Viral Diseases, NIAID, NIH).
The CD4-IgG2 (PRO 542) protein (1) was obtained from Progenics.
Sequences for all of the constructs are in Fig. S1 in the supplemental material;
schematic structures are shown in Fig. S1 and Table S1 in the supplemental
material. Genes encoding scFv versions of Abs E51, m9, and 21c were synthe-
sized as the VH domain followed by a (Gly4Ser)3 linker, the VL domain, and a
C-terminal six-His tag. CD4-scFv genes were constructed to be similar to the
CD4-scFv17b gene (11) by fusing the DNA encoding the CD4 hydrophobic leader
sequence and first two domains (D1-D2; residues 1 to 182 of the mature CD4
protein) to a (Gly4Ser)7 linker sequence followed by the His-tagged scFv con-
struct. The CD4-scFv17b gene was fused to the human IgG1 Fc domain sequence
by bridge PCR to create CD4-scFv17b-Fc.
CD4-IgG heavy chain constructs (denoted by the prefix CD4HC-) were made
by fusing the CD4-VH region of the 21c and E51 CD4-scFv constructs to the
remaining domains (CH1, CH2, and CH3) of a human IgG1 heavy chain gene
using bridge PCR. Analogous constructs for 412d and m9 were synthesized.
Bridge PCR was used to construct CD4-Fc [CD4 D1-D2 domains linked with
(Gly4Ser)7, denoted GS7 in the construct names, to the Fc region of IgG1].
CD4HC-(GS7)-IgG2G12 and CD4HC-(GS7)-IgGanti-gD were constructed by in-
serting sequences encoding the relevant VH and CH1 domains into the CD4-IgG
scaffold. The light chain (denoted LC in the constructs) of CD4LC-(GS7)-IgGE51
was constructed by bridge PCR.
A gene encoding a flexible linker [(Gly4Ser)9, denoted GS9] was synthesized
with NheI and BamHI restriction enzyme sites. The linker region sequence was
inserted between the CD4 and VH sequences of the CD4HC-(GS7)-IgGE51 con-
struct by subcloning, replacing the (Gly4Ser)7 sequence with the new linker
sequence.
Protein expression and purification. The CD4-scFv17b gene was subcloned
into baculovirus expression vector pBacPAK8 (BD Biosciences), and CD4-
scFv17b protein was purified from insect cell supernatants by Ni-nitrilotriacetic
acid (NTA) chromatography. All other constructs were subcloned into the mam-
malian expression vector pTT5 (NRC Biotechnology Research Institute), and
the corresponding proteins were expressed transiently in suspension HEK
293-6E cells (NRC Biotechnology Research Institute) using 25-kDa linear poly-
ethylenimine (PEI) (Polysciences) as described previously (12). When the het-
erodimeric constructs were expressed, the heavy chain and light chain vectors
were mixed at a 1:1 ratio by mass. Cell culture supernatants were collected 6 days
posttransfection. For Fc-containing constructs, supernatants were passed over
protein A resin (Thermo Fisher Scientific), eluted using pH 3.0 citrate buffer,
and then immediately neutralized. The scFv and CD4-scFv reagents were puri-
fied using Ni-NTA chromatography and eluted using 300 mM imidazole. All
reagents were then subjected to size exclusion chromatography in 20 mM Tris
(pH 8.0)–150 mM NaCl using a Superdex 200 16/60 or 10/30 column (GE
Healthcare). Final yields of purified reagents are given in Table S1 in the
supplemental material.
In vitro neutralization assays. A previously described pseudovirus neutraliza-
tion assay, which measures the reduction in luciferase reporter gene expression
in the presence of a potential inhibitor following a single round of pseudovirus
infection in TZM-bl cells (21, 23), was used to evaluate the neutralization
potencies of the reagents. Pseudoviruses were generated by cotransfection of
HEK 293T cells with an Env expression plasmid and a replication-defective
backbone plasmid. Neutralization assays were performed either by our labora-
tory (see Tables 1, 2, 4, and 5) or by the Collaboration for AIDS Vaccine
Discovery (CAVD) core neutralization facility (see Table 3) using the same
protocol (21, 23). Briefly, each sample was tested in triplicate (our assays) or
duplicate (CAVD assays), with 200 infectious viral units per well incubated with
a threefold dilution series and with 75 g/ml DEAE-dextran. For experiments
testing inhibition of 2G12 binding by fructose, the 1-h incubation at 37°C of
reagent plus pseudovirus was done in the presence of 3% (wt/vol) fructose. For
all assays, after a 1-h incubation at 37°C, 10,000 TZM-bl cells were added to each
well and incubated for 2 days. Cells were then lysed and assayed for luciferase
expression using BriteLite plus (PerkinElmer) and a Victor3 luminometer
(PerkinElmer) (our assays) or equivalent equipment (CAVD assays). Percentage
neutralization was determined by calculating the difference in luminescence
between test wells (cells plus virus plus reagent) and cell control wells (cells
only), dividing this value by the difference between the virus control wells (cells
plus virus) and cell control wells, subtracting from 1, and multiplying by 100.
Nonlinear regression analysis was used to calculate concentrations at which
half-maximal inhibition was observed (IC50s). Average IC50s across multiple
HIV-1 strains are reported as both arithmetic and geometric means. Calculation
of geometric means is suitable for data sets covering multiple orders of magni-
tude (31), as is the case for neutralization data across multiple viral strains. IC50s
are reported in Tables 1 to 5 as molar concentrations to compensate for different
molecular weights of the reagents. IC50s in g/ml are presented for the Table 3
data in Table S2 in the supplemental material.
Calculation of the IC50eff of a bivalent reagent. We calculated the effective
IC50 (IC50eff) for a reagent containing independently acting components with
individual IC50s of IC50a and IC50b. The fraction of Env binding sites occupied by
component a is [c]/(IC50a  [c]), where [c] is the concentration of the reagent.
Likewise, the fraction of sites occupied by component b is [c]/(IC50b  [c]). The
fraction occupied by components a and/or b is calculated as follows: [c]/(IC50a 
[c])  [c]/(IC50b  [c])  [c]2/((IC50a  [c])  (IC50b  [c])). Solving for [c]
when the fraction occupied by a and/or b equals 0.5 gives the following IC50eff:
IC50eff 	 0.5  (IC50a  IC50b  
(IC50a2  IC50b2  6  IC50a  IC50b)).
From Table 1, the geometric mean IC50s for CD4-scFvE51, CD4, and scFvE51 are
29, 210, and 110 nM, respectively. For IC50a of 210 nM (CD4) and IC50b of 110
nM (scFvE51), we calculate that the IC50eff is 61 nM. Hence, the average IC50 for
CD4-scFvE51, 29 nM, is about twofold better than the independent model would
predict. Using the IC50 of scFvE51 for the activity of the CD4i component of
CD4-scFvE51 might underestimate the synergy of the components since larger
CD4i reagents are thought to be significantly less potent than smaller ones (20).
TABLE 1. IC50s for CD4-scFv reagents
Env Clade
IC50 (nM)a
CD4-scFv17b CD4-scFvm9 CD4-scFv21c CD4-scFvE51 CD4 scFvE51
SF162.LS B 3.5 1.7 1.40 0.75 16 15
SC422661.8 B 91 ND 1200 24 480 61
TRJO4551.58 B 1000 720 1500 500 940* 320
QH0692.42 B 59 ND ND 31 110 450
RHPA4259.7 B 110 ND 370 48 170 76
ZM53M.PB12 C 200 150 880 60 390* 66
ZM214M.PL15 C 91 110 330 23 480 120
Du172.17 C 24 66 89 26 150 190
Geometric mean 70 66 220 29 210 110
Arithmetic mean 200 210 620 89 340 160
a Results are from in-house neutralization assays except for values marked with an asterisk, which are from CAVD core neutralization facility assays. ND, not
determined.
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Nucleotide sequence accession numbers. The 21c sequences have been depos-
ited in GenBank under accession numbers GU179344 and GU179345.
RESULTS
To determine which CD4i Ab combining sites formed effec-
tive CD4-scFv CD4i reagents, we expressed fusions of 17b,
E51, and m9 and evaluated these using an in vitro neutraliza-
tion assay (Table 1). In addition, we made a CD4-scFv reagent
using the CD4i Ab 21c, which was reported to be cross-reactive
and highly potent against HIV-2 (10), after isolating the heavy
and light chain genes encoding the Ab. All CD4-scFv reagents
consisted of the first two domains of CD4 (D1 and D2) fused
to an scFv with a (Gly4Ser)7 linker sequence (Fig. 1). Of these,
17b, E51, and m9 gave reagents with comparable potencies.
The geometric mean molar IC50 for CD4-scFvE51 (29 nM) is
significantly lower than that of CD4 alone (210 nM) or scFvE51
alone (110 nM) (Table 1), implying that both components are
contributing to the neutralization potency of this reagent. The
more weakly neutralizing 21c reagent was less effective (IC50 of
220 nM) than the other CD4-scFv reagents (IC50s of 29 to 70
nM). The lower efficacy of this reagent might result if the linker
in the CD4-scFv21c construct did not permit simultaneous
binding by the CD4 and 21c components, perhaps due to a
difference in the relative orientation of 21c on gp120 compared
to other CD4i antibodies.
Next, we evaluated the effects of including an Ab Fc domain,
which would convert a CD4-CD4i reagent into a dimer and
increase the serum half-life through binding of the Fc to the
protection receptor FcRn (7). Our initial Fc construct con-
sisted of the CD4-scFv17b sequence (11) fused to the N termi-
nus of the human IgG1 Fc domain to make CD4-scFv17b-Fc
(Fig. 1). In addition, we tried to express a two-chain reagent in
which CD4 was fused to the N terminus of the constant domain
of the light chain (CL), and the 17b scFv was fused to the N
terminus of the Fc domain. This two-chain form gave only
trace quantities of the desired protein product (data not
shown), whereas the single chain form, CD4-scFv17b-Fc,
yielded a small but testable quantity for neutralization assays
(see Table S1 in the supplemental material). These assays
demonstrated that CD4-scFv17b-Fc had a molar neutralization
potency about twofold better than CD4-scFv17b (for strain
QH-0692, the IC50s were 30 nM versus 59 nM, and for strain
SF162.LS, the IC50s were 2.5 nM versus 3.5 nM), as would be
expected if each half of the dimeric reagent functioned inde-
pendently. Hence, no enhancement due to avidity was ob-
served for this reagent.
Although the CD4-scFv17b-Fc reagent maintained its antivi-
ral activity and likely would have an increased serum half-life
due to the Fc domain, it had a relatively poor expression yield
(see Table S1 in the supplemental material), and its neutral-
ization properties suggested no evidence for an avidity effect.
Since we had observed that two-chain IgG reagents were often
expressed well, we designed a CD4-CD4i reagent with a more
IgG-like architecture by attaching CD4 to the N terminus of a
complete Ab heavy chain, which would be expressed together
with a conventional Ab light chain. The CD4HC-(GS7)-IgGE51
construct was expressed well (10 mg/liter), and we compared
the neutralization potencies of this reagent with CD4-scFvE51
(Table 2). CD4HC-(GS7)-IgGE51 had a molar neutralization
potency (mean IC50 of 3.1 nM) higher than what would be
expected for monovalent binding by only one arm of the re-
agent at a time (expected IC50 of 7.5 nM), suggesting that
this geometry allowed an avidity enhancement resulting from
simultaneous binding of both arms. Simultaneous binding
might have been facilitated by the greater distance between the
CD4 arms in this reagent compared to the CD4-scFv17b-Fc
construct.
To fully explore the potential of the IgG-like architecture,
we made additional reagents in which CD4 was fused to the N
terminus of the Ab light chain (CD4LC-(GS7)-IgGE51) or to
both the heavy chain and the light chain [CD4HC,LC-(GS7)-
IgGE51]. These reagents were expressed at yields of30% and
10% of the heavy chain CD4HC-(GS7)-IgGE51 form, and the
average neutralization potencies of these reagents were mod-
estly reduced compared to the original reagent (Table 2).
Using the CD4HC-(GS7)-IgGE51 reagent as a benchmark,
we next varied the linker between CD4 and the variable do-
main of the heavy chain (VH). We constructed a longer flexible
glycine-serine linker (Gly4Ser)9 to make CD4HC-(GS9)-
IgGE51. To more thoroughly evaluate these reagents, as well as
reagents containing 17b, m9, and 412d Ab combining sites in
place of E51, we compared neutralization potencies over a
panel of clade A, B, and C HIV-1 strains (Table 3). The
neutralization potency of the longer CD4HC-(GS9)-IgGE51
construct was slightly, but consistently, 30% better than
CD4HC-(GS7)-IgGE51 (P  0.001 [two-tailed paired t test on
log10-transformed values]).
To determine the degree to which the combining site of the
CD4i Ab contributed to the activity of CD4HC-(GS7)-IgGE51,
we constructed a similar reagent using an Ab against an irrel-
evant antigen (the herpes simplex virus gD protein) (4) to
create CD4HC-(GS7)-IgGanti-gD. Control experiments demon-
strated that the parental anti-gD Ab was inactive in HIV-1
neutralization assays (data not shown); thus, any potential neu-
tralization activity of the CD4HC-(GS7)-IgGanti-gD reagent
would be derived solely from its CD4 component. We also
evaluated the neutralization potencies of other reagents whose
neutralization activities would be solely due to CD4: the tet-
ravalent CD4-IgG2 reagent (also known as PRO 542) (1) and
a bivalent CD4-Fc construct similar to a previously described
CD4-immunoadhesin reagent (7) (Fig. 1). CD4HC-(GS7)-
IgGE51 had a geometric mean IC50 of 5 nM and was about
twofold more potent than the corresponding reagent lacking
CD4i Ab activity, CD4HC-(GS7)-IgGanti-gD, which had a geo-
TABLE 2. IC50s for CD4-IgGE51 constructs compared
to CD4-scFvE51
Env Clade
IC50 (nM)a
CD4-
scFvE51
CD4HC-
(GS7)-
IgGE51
CD4LC-
(GS7)-
IgGE51
CD4HC,LC-
(GS7)-
IgGE51
SF162.LS B 0.75 0.47 1.3 1.7
SC422661.8 B 24 16 30 47
QH0692.42 B 31 2.1 ND ND
RHPA4259.7 B 48 3.5 ND ND
Du172.17 C 26 4.9 5.5 32
Geometric mean 15 3.1 6.0 14
Arithmetic mean 26 5.4 12 27
a ND, not determined.
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metric mean IC50 of 11 nM (P  0.02, by a two-tailed paired t
test on log10-transformed values). We also found that the
CD4HC-(GS9)-IgGE51 and CD4HC-(GS7)-IgG17b reagents
were about threefold more potent than the CD4HC-(GS7)-
IgGanti-gD and CD4-IgG2 reagents lacking CD4i Ab combining
sites (all pairwise comparisons have P values of 0.0001) (Ta-
ble 3). However, the m9 and 412d reagents (CD4HC-(GS7)-
IgGm9 and CD4HC-(GS7)-IgG412d) were two– to threefold less
potent than either CD4-IgG2 or CD4HC-(GS7)-IgGanti-gD,
suggesting that the m9 and 412d combining sites were not
paired with CD4 to achieve optimal binding of the CD4 or Ab
components to gp120. All of these reagents were considerably
more potent than CD4-Fc, which had a geometric mean IC50
of 210 nM, compared with mean values of10 nM for the E51
and 17b CD4HC reagents (Table 3). A direct comparison be-
tween the two bivalent CD4-containing proteins with no CD4i
components [CD4HC-(GS7)-IgGanti-gD and CD4-Fc] demon-
strates that increasing the potential distance between the CD4
components yields a far more effective reagent (mean IC50 of
11 nM versus 210 nM). The fact that the bivalent CD4HC-
(GS7)-IgGanti-gD has a potentially longer CD4 separation dis-
tance than the tetravalent CD4-IgG2 reagent (Fig. 1) may
explain their similar neutralization potencies (mean IC50s of 11
nM and 14 nM) despite the greater number of CD4 moieties in
CD4-IgG2. Similarly, a longer CD4 separation distance com-
bined with the inclusion of CD4i components is likely to
account for the increased neutralization potencies of CD4HC-
(GS7)-IgG17b (mean IC50 of 2.9 nM) and CD4HC-(GS9)-
IgGE51 (mean IC50 of 2.9 nM) compared with CD4-IgG2
(mean IC50 of 14 nM) (Table 3).
In order to test a multivalent CD4 architecture with a dif-
ferent geometry, we constructed a fusion of CD4 D1-D2 with
the non-CD4i Ab 2G12, which recognizes a cluster of carbo-
hydrates on gp120 via a rigid (Fab)2 created by three-dimen-
sional domain swapping (6). Expression and purification of a
CD4 fusion to the 2G12 heavy chain yielded monomeric and
dimeric fractions similar to those observed with unmodified
2G12 IgG (Fig. 1) (37). The neutralization potencies of these
reagents (Table 4) suggested that both the CD4 components
and the antibody combining sites of these reagents contribute
to neutralization since (i) CD4HC-(GS7)-IgG2G12 is active on a
clade C stain (Du172.17) that is not neutralized by unmodified
2G12 monomers or dimers and since (ii) CD4HC-(GS7)-
IgG2G12 neutralizes the clade B TRO.11 strain 13-fold (2G12
monomer) and 150-fold (2G12 dimer) better than the pure
CD4-reagent CD4-IgG2 (PRO 542). The second observation
implies that either the 2G12 anticarbohydrate binding activity
is functional in CD4HC-(GS7)-IgG2G12 and/or that the geom-
etry of the CD4 components is more favorable than in the
CD4-IgG2 reagent. The more similar neutralization potencies
observed between CD4HC-(GS7)-IgG2G12 and CD4-IgG2 on
other strains suggest that differences in the CD4 geometries
are not likely to explain the TRO.11 results, suggesting that
carbohydrate recognition contributes to the neutralization po-
tencies of the CD4HC-(GS7)-IgG2G12 reagents against 2G12-
sensitive viral strains.
To confirm that antigen binding by 2G12 contributes to the
activity of CD4HC-(GS7)-IgG2G12, we conducted additional
neutralization assays in the presence of fructose, which has
been reported to inhibit 2G12 binding to its carbohydrate
epitope on gp120 (6). In order to observe a potential inhibitory
effect of fructose addition, we chose clade B strains that were
sensitive to 2G12. In the presence of 3% fructose, we observed
3- to 11-fold weaker neutralization of 2G12 IgG and CD4HC-
(GS7)-IgG2G12, whereas neutralization by CD4HC-(GS7)-
IgGE51, a CD4-CD4i reagent, was unaffected by including fruc-
tose (0.7- to 1.2-fold differences) (Table 5).
DISCUSSION
CD4-CD4i reagents are designed to allow both the CD4 and
CD4i components to bind gp120 simultaneously, in which case
neutralization of HIV-1 should occur at a lower concentration
TABLE 4. IC50s for CD4-2G12 constructs compared with 2G12-
only and CD4-only reagents
Env Clade
IC50 (nM)a
Monomer Dimer
CD4-
IgG22G12 CD4HC-IgG2G12
2G12 CD4HC-IgG2G12
PVO.4 B 33* 4.2* 0.17* 0.30* 27*
SC422661.8 B 140 4.4 0.38 0.46 7.3
QH0692.42 B 72 1.8 0.71 0.60 0.83
TRO.11 B 13 6.8 0.11 0.63 92
Du156.12 C 670* 530* 330* 260* 40*
Du172.17 C 670 6.3 330 1.1 2.5
Geometric mean 110 9.5 2.9 1.6 11
Arithmetic mean 270 92 110 44 28
a Results are from in-house neutralization assays except for values marked
with an asterisk, which are from CAVD core neutralization facility assays. In
calculating average IC50s, measurements outside of the range of the assay (in-
dicated by a  symbol) were assigned to that limiting value.
TABLE 5. IC50s for CD4HC-IgG2G12, 2G12, and CD4-CD4i reagents in the presence and absence of 3% fructose
Env
Effect on IC50 of fructosea
CD4HC-IgG2G12 monomer 2G12 monomer CD4HC-(GS7)-IgGE51
IC50 (nM) Fold
change
IC50 (nM) Fold
change
IC50 (nM) Fold
change     
WITO4160.33 200 18 11 650 65 10 110 91 1.2
SC422661.8 430 46 9.3 260 64 4.1 310 300 1.0
QH0692.42 16 6 2.7 130 44 3.0 18 27 0.7
TRO.11 28 5.7 4.9 33 5.3 6.2 ND ND ND
a , treatment with 3% fructose; , no fructose; ND, not determined.
266 WEST ET AL. J. VIROL.
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on January 8, 2010 
jvi.asm.org
D
ow
nloaded from
 
because the effective affinity of this type of bivalent reagent
would be increased compared to its components. In other
words, if binding of the CD4 portion of the reagent to gp120 is
in equilibrium, then binding of the CD4i portion to gp120
would reduce the rate at which the reagent dissociates from the
virus by either stabilizing the CD4-bound conformation or by
permitting rebinding of the CD4 component.
Our comparative study of the neutralization potencies of
various CD4-CD4i reagents allows an estimate of the en-
hanced potencies of these reagents resulting from potential
bivalent binding. Analysis of the neutralization activity of CD4-
scFvE51 compared to its CD4 and scFvE51 components suggests
about a twofold enhanced potency for the combined reagent
(see Materials and Methods), similar to the increased po-
tency of CD4HC-(GS7)-IgGE51 compared to CD4HC-(GS7)-
IgGanti-gD (Table 3). The relatively modest enhancement we
see for CD4-CD4i reagents compared to other bivalent re-
agents (neutralization potencies of IgG versus Fab can be up to
1,000-fold different for some viruses) (30) may be due to gp120
conformational changes associated with CD4 binding. First,
the CD4i Ab component is unlikely to bind unless CD4 is
already bound. Second, dissociation of CD4 may be quickly
followed by a conformational change in gp120 that eliminates
the CD4i binding site and thereby causes dissociation of the
whole CD4-CD4i reagent. In theory, the CD4-CD4i Ab fusion
protein can reduce the rate at which the reagent dissociates
from the virus by either stabilizing the CD4-bound conforma-
tion or by permitting rebinding of the CD4 component. These
mechanisms may be limited by the kinetics of gp120 confor-
mational change.
Although it is not yet clear if it is possible to enhance the
synergy between the components of a CD4-CD4i fusion pro-
tein, we were able to construct reagents with increased neu-
tralization potencies compared with CD4-scFv reagents. By
comparing the expression levels and efficacies of different
architectures of CD4-CD4i Ab fusion proteins (Fig. 1; see also
Table S1 in the supplemental material) in neutralization of a
broad range of primary HIV-1 strains, we found that including
an IgG Fc region improved the neutralization potency of a
CD4-CD4i reagent. In addition to dimerizing a CD4-CD4i
reagent, addition of Fc would also be expected to improve a
reagent’s serum half-life due to rescue from degradation via
binding to the neonatal Fc receptor, which serves as a protec-
tion receptor for IgGs and other Fc-containing proteins (26).
After testing several architectures for CD4-IgG constructs, we
found that reagents in which CD4 was linked to the heavy
chain of a CD4i Ab [i.e., CD4HC-(linker)-IgG] showed favor-
able expression characteristics and a low nanomolar geometric
mean IC50 across a broad range of primary HIV strains (Table
3). The polymeric reagent D1D2-Igtp has also been reported
to neutralize HIV strains very efficiently at low-nanomolar
concentrations (2), and even without binding to gp120 or virus,
this reagent exhibited a functionally irreversible association
with CD16 on natural killer cells (14). Although D1D2-Igtp
should be a powerful reagent for elimination of virally infected
cells, our monomeric reagents may have advantages for pro-
viding passive immunity (e.g., as smaller molecules there
should be more complete distribution to potential sites of
exposure).
We also compared our reagents to an existing set of broadly
neutralizing Abs (Table 3). We were unable to fully compare
our reagents with recently described highly potent broadly
neutralizing Abs (35) because the new Abs were tested on a
different panel of primary HIV-1 strains than used in our
study; however, IC50s are presented for the common strains
that were tested (Table 3). Three reagents, CD4HC-(GS7)-
IgGE51, CD4HC-(GS9)-IgGE51, and CD4HC-(GS7)-IgG17b,
neutralized a range of clade A, B, and C HIV-1 strains with
comparable if not higher potencies than the broadly neutral-
izing Abs and CD4-IgG2. Of the three new CD4-CD4i re-
agents, we achieved the highest expression levels for CD4HC-
(GS7)-IgGE51, suggesting that this reagent would be the best
suited for applications involving expression by gene therapy.
In addition to the CD4-CD4i fusion proteins, we tried fusing
CD4 to 2G12, an Ab that binds to a constellation of carbohy-
drates on gp120 using a domain-swapped (Fab)2 unit (6). We
previously showed that 2G12 forms stable dimers that exhibit a
50- to 80-fold increase in neutralization potency compared
with monomeric 2G12 against a collection of clade B HIV-1
strains, but that 2G12 dimers, like their monomeric counter-
parts, were unable to neutralize clade C HIV-1 strains (37).
We found that the CD4-2G12 fusion protein, similar to un-
modified 2G12, was expressed as a mixture of monomers and
dimers, with two and four antibody combining sites, respec-
tively (Fig. 1). The CD4HC-(GS7)-IgG2G12 proteins showed
nearly comparable (in the case of the dimer) or enhanced (in
the case of the monomer) neutralization potencies against
clade B HIV-1 strains, but most promisingly, fusion of CD4 to
2G12 conferred the ability to neutralize some clade C HIV-1
strains (Table 4).
The IgG-based CD4-CD4i and CD4-2G12 reagents re-
ported here represent a new class of anti-HIV-1 protein ther-
apeutics of potential use for passive immunization or gene
therapy efforts. The addition of CD4 conferred a broader
range of neutralization activity and/or facilitated binding of a
CD4i Ab. Comparison of CD4-CD4i reagents with CD4-only
reagents suggested that the addition of a CD4i Ab enhanced
the potency of CD4 reagents two- to threefold. The moderate
degree of synergy may be related to a nonoptimal geometry
between the CD4 and CD4i Ab components; thus, alternative
linkers may be more efficient for promoting simultaneous bind-
ing. Also, since we sometimes observed partial degradation of
the CD4-CD4i reagents on storage (A. P. West, Jr., R. P.
Galimidi, and P. J. Bjorkman, unpublished observations), im-
provement of the linker design may yield more stable and
potent reagents.
The maximal potential potency of CD4-CD4i reagents may
be inherently limited by kinetic factors or other properties; for
example, in the trimeric envelope spike, engagement of mul-
tiple CD4 molecules might be required to elicit the conforma-
tional change that exposes the coreceptor binding sites. Fur-
thermore, binding studies involving trimeric Env proteins and
CD4 and/or a CD4i Ab have revealed unexpected stoichiom-
etries. For example, only a single CD4i Fab X5 bound to an
HIV-1 Env trimer complexed with three CD4 molecules (9),
apparently reflecting steric constraints on CD4i Ab binding to
Env trimers. Recently, a specific mechanism of action for sol-
uble CD4 and CD4-mimetic compounds was discovered; en-
gagement with these reagents causes a short-lived activated
state of Env trimers that is followed by irreversible decay into
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a nonfunctional form (15). A greater understanding of steric
and other factors that limit the activity of CD4-CD4i reagents
would facilitate design of bispecific reagents with increased
potency relative to the individual components.
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